{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.5"},{"groupId":"OG001","value":"36.6"},{"groupId":"OG002","value":"43.1"},{"groupId":"OG003","value":"33.3"},{"groupId":"OG004","value":"54.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"67"}],"units":"Participants"}],"title":"Baseline (BL): Non/absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2"},{"groupId":"OG001","value":"17.8"},{"groupId":"OG002","value":"25.2"},{"groupId":"OG003","value":"21.1"},{"groupId":"OG004","value":"25.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"31"}],"units":"Participants"}],"title":"BL: Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7"},{"groupId":"OG001","value":"26.0"},{"groupId":"OG002","value":"18.7"},{"groupId":"OG003","value":"26.0"},{"groupId":"OG004","value":"10.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"13"}],"units":"Participants"}],"title":"BL: Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"13.8"},{"groupId":"OG002","value":"8.9"},{"groupId":"OG003","value":"16.3"},{"groupId":"OG004","value":"8.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"11"}],"units":"Participants"}],"title":"BL: Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"4.9"},{"groupId":"OG002","value":"4.1"},{"groupId":"OG003","value":"3.3"},{"groupId":"OG004","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"BL: Very severe"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"BL: Not done"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"groupId":"OG004","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"123"},{"groupId":"OG003","value":"123"},{"groupId":"OG004","value":"123"}],"units":"Participants"}],"title":"BL: Total"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6"},{"groupId":"OG001","value":"26.0"},{"groupId":"OG002","value":"37.4"},{"groupId":"OG003","value":"26.8"},{"groupId":"OG004","value":"47.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"58"}],"units":"Participants"}],"title":"Most extr post-BL:tot Non/absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9"},{"groupId":"OG001","value":"22.8"},{"groupId":"OG002","value":"29.3"},{"groupId":"OG003","value":"26.0"},{"groupId":"OG004","value":"27.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"34"}],"units":"Participants"}],"title":"Most extr. post-BL: total Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3"},{"groupId":"OG001","value":"22.8"},{"groupId":"OG002","value":"20.3"},{"groupId":"OG003","value":"24.4"},{"groupId":"OG004","value":"13.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"16"}],"units":"Participants"}],"title":"Most extr. post-BL: total Mod."},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8"},{"groupId":"OG001","value":"15.4"},{"groupId":"OG002","value":"7.3"},{"groupId":"OG003","value":"14.6"},{"groupId":"OG004","value":"9.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"12"}],"units":"Participants"}],"title":"Most extr. post-BL: total Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"13.0"},{"groupId":"OG002","value":"5.7"},{"groupId":"OG003","value":"8.1"},{"groupId":"OG004","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Most extr post-BL:tot. Very severe"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Most extr. post-BL: total Not done"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"123"},{"groupId":"OG003","value":"123"},{"groupId":"OG004","value":"123"}],"units":"Participants"}],"description":"Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).","groups":[{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG000","title":"Pasireotide LAR Overall - Acromegaly Symptom: Headache"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG001","title":"Pasireotide LAR Overall - Acromegaly Symptom: Fatigue"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG002","title":"Pasireotide LAR Overall - Acromegaly Symptom: Perspiration"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG003","title":"Pasireotide LAR Overall - Acromegaly Symptom: Osteoarthralgia"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG004","title":"Pasireotide LAR Overall - Acromegaly Symptom: Paresthsiae"}],"paramType":"NUMBER","populationDescription":"FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study","reportingStatus":"POSTED","timeFrame":"Weeks 12, 24 & 36","title":"Core Phase: Percentage of Participants With Acromegaly Shift Symptoms From Baseline to Most Extreme Post-baseline","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}